Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow 2seventy bio, Inc.

Get SEC filing alerts via email and in your feed for 2seventy bio, Inc.

TSVT

2seventy bio, Inc.

About 2seventy bio, Inc.

2seventy bio, Inc. is a cell therapy company focused on the commercialization of Abecma, the first FDA-approved CAR T cell therapy for multiple myeloma. With a significant market opportunity, the company targets patients with relapsed or refractory disease. Recent strategic initiatives include partnerships with Bristol-Myers Squibb for commercialization and the sale of non-core assets to enhance focus on Abecma's development and market presence.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from 2seventy bio, Inc.

1
1
2seventy bio, Inc. 2seventy Bio Reports Revenue Growth to $22.9 Million in Q1 2025, Prepares for Merger with BMS

Via official filing (AI summary) | about 1 year ago | 0 comments

2
1
2seventy bio, Inc. 2seventy Bio Reports Revenue Decline to $37.9 Million, Focuses on Abecma Commercialization

Via official filing (AI summary) | over 1 year ago | 0 comments

3
1
2seventy bio, Inc. 2seventy bio Reports Decreased Assets, Improved Losses, and Focus on Abecma Development

Via official filing (AI summary) | over 1 year ago | 0 comments